权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bacterial cell killing by topoisomerase I mediated DNA lesion

拓扑异构酶 I 介导的 DNA 损伤杀死细菌细胞

基本信息

批准号：
7169238
负责人：
Yuk-Ching Tse-Dinh
金额：
$ 37.6万
依托单位：
NEW YORK MEDICAL COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-02-01 至 2011-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7169238
关键词：
Anti-Bacterial Agents Antibiotics Bacteria Bacterial DNA Topoisomerase I Bacterial Typing Biological Assay Cells Class Cleaved cell Collaborations Community Hospitals Complex Condition DNA DNA Fingerprinting DNA Topoisomerases DNA biosynthesis DNA lesion Development Emerging Communicable Diseases Enzymes Escherichia coli Face Future General Population Genes Genetic Recombination Genetic Transcription Genomic Library Goals Gram-Negative Bacteria Growth In Vitro Infection Laboratories Lead Lesion Libraries Malignant Neoplasms Measurement Mediating Modeling Monitor Mutagenesis Mutation Pathway interactions Personal Satisfaction Plasmids Predisposition Prevention Protein Biosynthesis Proteins Public Health Pulsed-Field Gel Electrophoresis Recombinants Research Research Personnel Resistance Role Screening procedure Therapeutic Agents Topoisomerase Type I DNA Topoisomerases Yersinia pestis bactericide biodefense cell killing cellular targeting desire follow-up genetic strain human TOP1 protein killings medical schools mutant novel novel therapeutics pathogen pathogenic bacteria programs recombinational repair response small molecule

项目摘要

DESCRIPTION (provided by applicant): DNA topoisomerases are ubiquitous enzymes involved in DNA replication, transcription and recombination. It is well known that trapping of covalent complexes formed between cleaved DNA and type II or type IB DNA topoisomerases by therapeutic agents leads to the killing of cancer or bacterial cells. The class of type IA DNA topoisomerases is a promising target for novel therapeutic agents, but molecules targeting type IA DNA topoisomerases have not been discovered. We have identified a mutant of Yersinia pestis topoisomerase I that can result in extensive killing when expressed in E. coli cells due to the stabilization of the covalent complex with cleaved DNA. This is the first demonstration of bacterial cell killing from accumulated covalent complex formed by a type IA DNA topoisomerase. The specific aims of the project are: 1. A high-through-put assay will be utilized at the NSRB facility at Harvard Medical School to screen the 150,000 compounds available for small molecules that will result in accumulation of covalent complex formed by recombinant Yersinia pestis topoisomerase I. Hits will be characterized by in vitro topoisomerase assay and bacterial cell killing and further developed in collaboration with medicinal chemists at NSRB. 2. To investigate the mechanism of bacterial cell killing by stabilized type IA DNA topoisomerase covalent complex, E. coli expressing the mutant Y. pestis topoisomerase I that forms the stabilized covalent complex will be studied. Sensitivity to topoisomerase I induced DNA lesion will be compared under different growth conditions to determine the role of DNA replication and protein synthesis in the cell killing mechanism. 3. To identify other factors influencing the susceptibility of bacteria to killing by trapped type IA topoisomerase cleaved complex, E. coli strains with mutations in recombination and repair pathways will be studied. An E. coli genomic library in a multi-copy plasmid will be used to identify proteins that when expressed in a higher level, can confer resistance to topoisomerase I mediated cell killing. Transposon mutagenesis will be carried out to screen for mutants with increased sensitivity or resistance to the cell killing. The emergence of pathogenic bacteria resistant to all common antibiotics represents a critical challenge in public health. Future terrorist attacks employing bacterial pathogens could involve agents resistant to current antibiotics. This research has the potential to lead to the discovery of a novel class of antibiotics.

描述（由申请人提供）：DNA拓扑异构酶是参与DNA复制、转录和重组的普遍存在的酶。众所周知，治疗剂捕获切割的DNA和II型或IB型DNA拓扑异构酶之间形成的共价复合物导致杀死癌细胞或细菌细胞。IA型DNA拓扑异构酶是一种很有前途的新型治疗药物靶点，但尚未发现靶向IA型DNA拓扑异构酶的分子。我们已经鉴定了鼠疫耶尔森氏菌拓扑异构酶I的一个突变体，当在大肠杆菌中表达时，它可以导致广泛的杀伤。由于共价复合物与切割的DNA的稳定性，这是第一次证明由IA型DNA拓扑异构酶形成的累积共价复合物杀死细菌细胞。该项目的具体目标是：1。在哈佛医学院的NSRB设施中，将使用高通量测定法筛选150，000种可用于小分子的化合物，这些小分子将导致重组鼠疫耶尔森氏菌拓扑异构酶I形成的共价复合物的积累。命中将通过体外拓扑异构酶测定和细菌细胞杀伤来表征，并与NSRB的药物化学家合作进一步开发。2.为探讨IA型DNA拓扑异构酶共价复合物对细菌细胞的杀伤作用机制，coli中表达突变体Y.将研究形成稳定的共价复合物的鼠疫拓扑异构酶I。比较不同生长条件下对拓扑异构酶I诱导的DNA损伤的敏感性，以确定DNA复制和蛋白质合成在细胞杀伤机制中的作用。3.为了确定其他影响细菌对IA型拓扑异构酶切割复合物杀伤敏感性的因素，E。将研究在重组和修复途径中具有突变的大肠杆菌菌株。大肠多拷贝质粒中的大肠杆菌基因组文库将用于鉴定当以较高水平表达时可赋予对拓扑异构酶I介导的细胞杀伤的抗性的蛋白质。将进行转座子诱变以筛选对细胞杀伤具有增加的敏感性或抗性的突变体。对所有常见抗生素产生耐药性的病原菌的出现是公共卫生领域的一个重大挑战。未来使用细菌病原体的恐怖袭击可能涉及对当前抗生素具有耐药性的制剂。这项研究有可能导致发现一类新的抗生素。